Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients With Advanced Dry-Form Age-Related Macular Degeneration (Geographic Atrophy)

Trial Profile

Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients With Advanced Dry-Form Age-Related Macular Degeneration (Geographic Atrophy)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Retinal pigment epithelial cell replacement therapy-Cell Cure Neurosciences (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Lineage Cell Therapeutics; Roche
  • Most Recent Events

    • 13 Mar 2024 According to a Lineage Cell Therapeutics media relea, 24 Month results of patients enrolled in a Phase 1/2a clinical study will be presented at 2024 Retinal Cell & Gene Therapy Innovation Summit by David Telander, MD, PhD, Retinal Consultants Medical Group, on behalf of Roche and Genentech.
    • 16 Jan 2024 According to a Lineage Cell Therapeutics media release, results from this trial will be presented at the 2024 Angiogenesis, Exudation, and Degeneration Meeting. The virtual meeting will be held on February 3, 2024.
    • 24 Oct 2023 According to a Lineage Cell Therapeutics media release, results of imaging analyses from this trial, have been accepted for presentation at Eyecelerator 2023, will be presented as part of the Presenting Company Breakout Session, between 1-2:45pm PDT, by Gary S. Hogge, D.V.M., M.S. Ph.D., Lineage's Senior Vice President, Clinical and Medical Affairs, at American Academy of Ophthalmology (AAO) 2023 Annual Meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top